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PositiveMetastatic Breast Cancer
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IMPORTANCE Randomized clinical trials have demonstrated a substantial benefit of adding
everolimus to endocrine therapy. Everolimus inhibits themammalian target of rapamycin
complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop
via mTORC2. Vistusertib, a dual inhibitor of mTORC1 andmTORC2, has demonstrated broad
activity in preclinical breast cancer models, showing superior activity to everolimus.
OBJECTIVE To evaluate the safety and efficacy of vistusertib in combination with fulvestrant
compared with fulvestrant alone or fulvestrant plus everolimus in postmenopausal women
with estrogen receptor–positive advanced or metastatic breast cancer.
DESIGN, SETTING, AND PARTICIPANTS TheMANTA trial is an open-label, phase 2 randomized
clinical trial in which 333 patients with estrogen receptor–positive breast cancer progressing
after prior aromatase inhibitor treatment underwent randomization (2:3:3:2) between April 1,
2014, and October 24, 2016, at 88 sites in 9 countries: 67 patients were assigned to receive
fulvestrant, 103 fulvestrant plus vistusertib daily, 98 fulvestrant plus vistusertib
intermittently, and 65 fulvestrant plus everolimus. Treatment was continued until disease
progression, development of unacceptable toxic effects, or withdrawal of consent. Analysis
was performed on an intention-to-treat basis.
INTERVENTIONS Fulvestrant alone or in combination with vistusertib (continuous or
intermittent dosing schedules) or everolimus.
MAIN OUTCOMES ANDMEASURES The primary end point was progression-free survival (PFS).
RESULTS Among the 333 women in the study (median age, 63 years [range, 56-70 years]),
median PFS was 5.4months (95% CI, 3.5-9.2 months) with fulvestrant, 7.6 months (95% CI,
5.9-9.4months) with fulvestrant plus daily vistusertib, 8.0months (95% CI, 5.6-9.9months)
with fulvestrant plus intermittent vistusertib, and 12.3 months (95% CI, 7.7-15.7 months) with
fulvestrant plus everolimus. There was no significant difference in PFS between those
receiving fulvestrant plus daily or intermittent vistusertib and fulvestrant alone (hazard ratio,
0.88 [95% CI, 0.63-1.24]; P = .46; and hazard ratio, 0.79 [95% CI, 0.55-1.12]; P = .16).
CONCLUSIONS AND RELEVANCE The combination of fulvestrant plus everolimus
demonstrated significantly longer PFS compared with fulvestrant plus vistusertib or
fulvestrant alone. The trial failed to demonstrate a benefit of adding the dual mTORC1 and
mTORC2 inhibitor vistusertib to fulvestrant.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02216786 and EudraCT number: 2013-
002403-34
JAMA Oncol. doi:10.1001/jamaoncol.2019.2526
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R
esistance to endocrine therapy remains a major clini-
cal challenge in women with hormone receptor–
positive advancedormetastatic breast cancer. There is
increasing evidence that aberrant signaling through the
phosphatidylinositol 3-kinase (PI3K)–mammalian target of ra-
pamycin (mTOR) signaling pathway plays a critical role in
endocrine resistance.1Approximately 50%of estrogen recep-
tor (ER)–positive primary breast cancers show abnormal in-
trinsic activation of the PI3K-mTOR pathway and many pa-
tients with advanced or metastatic breast cancer develop
acquired upregulation of PI3K-mTOR signaling.2-4
Preclinical investigation demonstrates that inhibition of
mTOR can overcome endocrine resistance.5-9 Clinical trials
have demonstrated a substantial benefit of adding themTOR
inhibitor everolimus to endocrine agents, especially in endo-
crine-resistant breast cancer.10-12 Everolimus is indicated for
the treatment of hormone receptor–positive, ERBB2/HER2-
negative advancedbreast cancer in combinationwithexemes-
tane in postmenopausal women without symptomatic vis-
ceral disease after recurrence or progression after treatment
with a nonsteroidal aromatase inhibitor (AI).
The mTOR kinase forms 2 distinct multiprotein com-
plexes,mammalian target of rapamycin complex 1 (mTORC1)
andmTORC2.Current clinicalmTORinhibitors suchaseveroli-
mus inhibit the mTORC1 complex only through an indirect
mechanism that doesnot involve themTORkinase, and there
is increasing evidence that thismechanism sets off a negative
feedback loop leading to theactivationofmTORC2,AKTphos-
phorylation, and ultimately treatment resistance.13 Preclini-
cal studies have demonstrated that rapamycin analogues are
unable to completely abrogate mTORC1 signaling and the re-
sidual activity of the downstream effector 4E-BP1 can con-
tinue to initiate protein translation.14Mammalian target of ra-
pamycinkinase inhibitorshavebeendeveloped toenhance the
antitumor activity through more complete TORC1 inhibition
and abrogating AKT-mediated TORC2 activation.
Vistusertib (AZD2014) is a dual inhibitor of both
mTORC1 and mTORC2 complexes15; compared with everoli-
mus, vistusertib has demonstrated more complete growth
inhibition and cell death in vitro and in vivo based on a
greater inhibitory function against mTORC1 and additional
inhibition of mTORC2, especially in ER-positive breast can-
cer models.16
Most preclinical and clinical applications of PI3K inhibi-
tors or mTOR inhibitors use continuous daily dosing sched-
ules. However, high-dose pulsatile administration has been
proposed as a way to induce more complete suppression of
mTOR signaling to maximize therapeutic benefit while
reducing toxic effects by allowing for recovery of nontarget
tissues during dosing breaks.17,18 Using intermittent dosing
(2 days on and 5 days off), vistusertib induced rapid tumor
regression in preclinical models.16 The shorter half-life of
vistusertib (mean, 3.3 hours) compared with other mTOR
inhibitors enables pulsatile administration of the medica-
tion. The maximum tolerated doses for both continuous
daily and intermittent dosing of vistusertib was established
in phase 1 studies with substantial antitumor activity dem-
onstrated for both schedules.16
The MANTA trial evaluated whether the addition of vis-
tusertib (AZD2014) increases progression-free survival (PFS)
andothermeasuresofantitumoractivityof fulvestrant inpost-
menopausal women with ER-positive advanced or meta-
staticbreast cancerwhohave failedprior therapywithAIs.The
study also evaluatedwhether dual inhibition ofmTORC1 and
mTORC2 with vistusertib leads to improved efficacy com-
paredwithmTORC1 inhibitionwith everolimus and explored
whether high-dose pulsatile dosing of vistusertib can in-
crease the activity and/or improve tolerability comparedwith
continuous daily treatment.
Methods
Study Design and Participants
In the MANTA trial, an investigator-led, open-label, ran-
domized phase 2 trial, patients were recruited between April
1, 2014, andOctober 24, 2016, in88centers in theUnitedKing-
dom, Spain, Germany, South Korea, France, Portugal, Hun-
gary, Romania, and Georgia (trial protocol in Supplement 1).
PostmenopausalwomenwithER-positive, locally advancedor
metastatic breast cancer were eligible if they either relapsed
while undergoing or within 12months of the end of adjuvant
treatment with an AI or progressed on treatment with an AI.
Any number of lines of hormonal therapy were allowed and
AI therapy did not have to be the last treatment prior to ran-
domization. Prior chemotherapy in the adjuvant or neoadju-
vant settingand1 lineofprior chemotherapy formetastaticdis-
easewere allowed.Measurable or evaluabledisease according
to Response Evaluation Criteria in Solid Tumors, version 1.1
(RECIST 1.1)19 and adequate hematologic, hepatic, and renal
function, andanEasternCooperativeOncologyGroupperfor-
mance status of 0 to 2 were required. Patients with life-
threateningmetastatic visceral disease, activeor treatedbrain
metastases, significantpulmonarydysfunction, significantcar-
diac disease, QT prolongation, type 1 diabetes or uncon-
trolled type 2 diabetes, and previous treatment with fulves-
trant, exemestane, mTOR, PI3K, or AKT inhibitors were
Key Points
Question Does the addition of vistusertib increase
progression-free survival and other measures of antitumor activity
of fulvestrant in postmenopausal womenwith estrogen
receptor–positive advanced or metastatic breast cancer that
progressed after prior therapy with aromatase inhibitors?
Findings This randomized clinical trial in 333 patients failed to
demonstrate a benefit of vistusertib plus fulvestrant vs fulvestrant
alone. In addition, the outcomes in both vistusertib groups were
inferior to those in the group treated with fulvestrant plus
everolimus.
Meaning The results suggest that dual mammalian target of
rapamycin inhibition with vistusertib at themaximal tolerated
doses is inferior to mammalian target of rapamycin complex 1
inhibition with the rapamycin analogue everolimus.
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excluded.All patientsprovidedwritten informedconsent.The
relevant institutional reviewboards andethics committees for
the88participatingcentersapprovedthestudy,whichwascon-
ducted in accordance with the principles of Good Clinical
Practice,20 theprovisions of theDeclarationofHelsinki,21 and
otherapplicable local regulations.TheBartsExperimentalCan-
cer Medicine Centre had overall responsibility for trial man-
agement; the Trial Management Group was responsible for
day-to-day running of the trial, and the trial was overseen by
an independent trial steering committee. Safety data were
reviewed regularly by the trial steering committee and an
independent data monitoring committee.
Randomization
Patients were randomized via InteractiveWeb Response Sys-
tem (2:3:3:2) to receive fulvestrant, fulvestrant plus vistu-
sertib (daily or intermittent), or fulvestrant plus everolimus,
respectively.Computer-generatedpermutedblockswereused
with stratificationbydiseasemeasurability andprevious sen-
sitivity to endocrine therapy, defined as at least 24months of
endocrine therapy before recurrence in the adjuvant setting,
complete or partial response to prior metastatic endocrine
treatment, or stabilization for at least 24 weeks of endocrine
therapy for advanced disease.
Procedures
Fulvestrant was given as a 500-mg intramuscular injection
loading dose on day 1, followed by 500-mg injections on days
15 and 29. Thereafter, 500-mg intramuscular injections were
given every 28 days. Everolimus was given orally once daily
at a dose of 10 mg. The continuous daily schedule of vistu-
sertib was given orally twice daily at a dose of 50 mg. Inter-
mittent vistusertib was given orally twice daily on days 1 and
2 of everyweek at a dose of 125mg. Treatmentwas continued
until disease progression, unacceptable toxic effects, or
withdrawal of consent. The protocol provided detailed
guidelines for dose interruptions or reductions for vistu-
sertib and everolimus; dose adjustments for fulvestrant
followed local guidelines.
The primary end point was PFS based on results of radio-
graphic studies assessedby the local investigators,with inde-
pendent central assessment on a subset of patients. Progres-
sion-free survivalwas defined as time from randomization to
disease progression or death from any cause, whichever oc-
curred first. Secondary end points included overall survival
(OS), objective response rate, clinical benefit rate, duration of
response, clinical benefit, and safety.
TumorassessmentwithRECIST 1.1 includedcomputed to-
mography scanning or magnetic resonance imaging of the
chest, abdomen, and pelvis at baseline, every 8weeks during
the first 40 weeks, and every 12 weeks thereafter until dis-
ease progression. Patients who discontinued 1 or both study
treatments for any reason other than progression of disease
were required to follow the same schedule of assessmentsun-
til progression.
Patients were monitored for adverse events (AEs) and
changes in laboratory test values, electrocardiogram results,
andphysicalexaminationfindings.Adverseeventsweregraded
according to National Cancer Institute Common Toxicity Cri-
teria (version 4.03)22 and coded with the Medical Dictionary
for Regulatory Activities.23
Statistical Analysis
Sample size was based on detecting an improvement in me-
dian PFS from 3.7 to 11.1 months (hazard ratio [HR], 0.40) in
patients allocated to receive fulvestrant plus vistusertib (ana-
lyzed separately for each schedule) compared with fulves-
trantalone, anddetectingan improvement inmedianPFS from
7.4 to 11.1 months (HR, 0.67) in patients allocated to receive
fulvestrant plus vistusertib compared with fulvestrant plus
everolimus.Withaminimumfollow-upof 18months, a5%sig-
nificance level (1-sided), and 99% power, a total of 130 PFS
events in the fulvestrant plus vistusertib and fulvestrant com-
parison were needed for the principal analysis. For the com-
parison of fulvestrant plus vistusertib vs fulvestrant plus
everolimus, 120 PFS events were needed based on a fol-
low-up of 18 months, a 10% significance level (1-sided), and
80% power.
Principal efficacy analyses included all randomized pa-
tients on an intention-to-treat basis, with patients analyzed
according to the treatment group towhich theywere random-
ized. Survival endpointswere showngraphicallywithKaplan-
Meier plots, and treatment comparisons were made with the
log-rank test. Hazard ratios were obtained from Cox propor-
tional hazards regression models, with HRs of less than 1 fa-
voring fulvestrant plus vistusertib in the comparisonwith ful-
vestrant alone, and fulvestrant plus everolimus in the
comparison with fulvestrant plus vistusertib.
Safety analyses includedall patientswho received at least
1 dose of trial treatment. The worst grade of AE during trial
treatmentwas reportedandcomparedwithFisher exact tests.
All prespecified toxic effects and any Medical Dictionary for
Regulatory Activities–coded event satisfying predefined cri-
teria are presented.
Results
BetweenApril 1, 2014, andOctober 24, 2016, 333 patients un-
derwent randomization (Figure 1): 67 patients were assigned
to receive fulvestrant, 103 fulvestrantplusvistusertibdaily, 98
fulvestrant plus vistusertib intermittently, and 65 fulvestrant
plus everolimus. Baseline distributions of patient and tumor
characteristics were similar in the treatment groups (eTable 1
in Supplement 2). Median age was 63 years; 202 of 326 pa-
tientshadvisceral involvement (62.0%)and254of326 (77.9%)
hadmeasurable disease. A total of 103 of 325 patients (31.7%)
hadmetastases in at least 3 organs andmost patients had re-
ceived systemic therapy for metastatic breast cancer. A total
of 282 of 326 patients (86.5%) had previous sensitivity to en-
docrine therapy.
At the cutoff date (October 13, 2017), 43 patients (12.9%)
were still receiving study treatment: 25 of 196 (12.8%) in the
fulvestrant plus vistusertib groups, 11 of 64 (17.2%) in the ful-
vestrant plus everolimus group, and 7of 66 (10.6%) in the ful-
vestrant alone group (eTable 1 in Supplement 2). Ahigher per-
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centage of patients in the 3 combination groups discontinued
study treatment becauseofAEsorwithdrawal of consent (ful-
vestrantplusdailyvistusertib, 18of 101 [17.8%]; fulvestrantplus
intermittent vistusertib, 16 of 95 [16.8%]; and fulvestrant plus
everolimus, 12 of 64 [18.8%]) comparedwith patients treated
with fulvestrant alone (6 of 66 [9.1%]),withno significant dif-
ferences between the combination groups. Treatment adher-
encewas comparablebetween the3 combinationgroups,with
3% to 5% of Investigational Medicinal Product doses being
missed and 28.4% to 33.7% of patients (fulvestrant plus daily
vistusertib, 34of 101 [33.7%]; fulvestrantplus intermittentvis-
tusertib, 27 of 95 [28.4%]; and fulvestrant plus everolimus, 21
of 64 [32.8%]) requiring at least 1 dose reduction of vistu-
sertib or everolimus.
Frequency of AEs (any grade) and severe AEs (grade 3 or
4) was higher in patients assigned to the combination
groups than in those assigned to receive fulvestrant alone
(eTable 2 in Supplement 2). The most common grade 3 or 4
AEs in the combination groups were stomatitis (12 of 92
[13.0%] in vistusertib daily group vs 4 of 92 [4.3%] in vistu-
sertib intermittent group vs 7 of 60 [11.7%] in everolimus
group), rash (19 of 92 [20.7%] vs 4 of 92 [4.3%] vs 3 of 60
[5.0%]), asthenia (2 of 92 [2.2%] vs 5 of 92 [5.4%] vs 2 of 60
[3.3%]), diarrhea (2 of 92 [2.2%] vs 5 of 92 [5.4%] vs 1 of 60
[1.7%]), hyperglycemia (4 of 92 [4.3%] vs 3 of 92 [3.3%] vs 2
of 60 [3.3%]), infection (5 of 92 [5.4%] vs 1 of 92 [1.1%] vs 4
of 60 [6.7%]), dyspnea (3 of 92 [3.3%] vs 0% vs 0%), and
nausea (0% vs 3 of 92 [3.3%] vs 0%). Intermittent dosing of
vistusertib was associated with a lower rate of rash or sto-
matitis but a higher rate of nausea and vomiting than daily
dosing of vistusertib.
After amedian follow-up inallpatientsof 17.1months (95%
CI, 15.9-18.3 months), 255 progression events were reported:
57 in patients assigned to fulvestrant, 81 in those assigned to
fulvestrant plus vistusertib daily, 72 in those assigned to ful-
vestrant plus vistusertib intermittently, and 45 in patients as-
signed to fulvestrant plus everolimus.
Median PFS in patients assigned to fulvestrant alone was
5.4 months (95% CI, 3.5-9.2 months), 7.6 months (95% CI,
5.9-9.4 months) in those assigned to fulvestrant plus daily
vistusertib, 8.0 months (95% CI, 5.6-9.9 months) in those
assigned to fulvestrant plus intermittent vistusertib, and 12.3
Figure 1. CONSORTDiagram
430 Patients screened
333 Randomized
103 Assigned to fulvestrant plus daily
vistusertib
98 Assigned to fulvestrant plus 
intermittent vistusertib
65 Assigned to fulvestrant plus 
everolimus
67 Assigned to fulvestrant 
101 Treated with fulvestrant plus
daily vistusertib
95 Treated with fulvestrant plus
intermittent vistusertib
64 Treated with fulvestrant plus 
everolimus
66 Treated with fulvestrant 
11 Still undergoing treatment 14 Still undergoing treatment 7 Still undergoing treatment 11 Still undergoing treatment
90 Discontinued
65 Progression
10 Decision by patient
or investigator
2 Death
8 Adverse events
5 Other
2 Did not start treatment
because they were ineligible
3 Did not start treatment
because they withdrew
consent
1 Did not start treatment
because they withdrew
consent
1 Did not start treatment
owing to poor health
81 Discontinued
57 Progression
12 Decision by patient
or investigator
3 Death
4 Adverse events
5 Other
59 Discontinued
52 Progression
5 Decision by patient
or investigator
1 Adverse events
1 Other
53 Discontinued
37 Progression
7 Decision by patient
or investigator
2 Death
5 Adverse events
2 Other
97 Excluded
21 Clinical laboratory finding 
9 Contraindicated comorbidity
11 No measurable disease 
10 Declined to participate 
8 Poor general health
3 Disease not refractory to aromatase inhibitors
6 LVEF <50%
5 Disease not ER positive, ERBB2/HER2-negative
3 Extensive hepatic metastases
2 QTc prolongation
3 Prohibited concomitant medication
2 >1 Line of prior chemotherapy for metastatic breast cancer
13 Unknown
1 Not postmenopausal
LVEF indicates left ventrical ejection fraction.
Research Original Investigation Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone in Metastatic Breast Cancer
E4 JAMAOncology Published online August 29, 2019 (Reprinted) jamaoncology.com
Downloaded From: https://jamanetwork.com/ by a University of Sheffield User  on 08/30/2019
months (95% CI, 7.7-15.7 months) in those assigned to fulves-
trant plus everolimus (Table). No significant difference in PFS
was seen between the patients assigned to receive fulvestrant
plus daily vistusertib and those who received fulvestrant
alone (HR, 0.88 [95% CI, 0.63-1.24]; log-rank P = .46),
between patients assigned to receive fulvestrant plus inter-
mittent vistusertib and those who received fulvestrant alone
(HR, 0.79 [95% CI, 0.55-1.12]; log-rank P = .16), and between
both fulvestrant plus vistusertib groups (HR, 1.11 [95% CI,
0.81-1.52]; log-rank P = .52). Progression-free survival was
significantly longer in patients assigned to fulvestrant plus
everolimus compared with fulvestrant plus daily vistusertib
(HR, 0.63 [95% CI, 0.45-0.90; log-rank P = .01) and those
assigned to fulvestrant plus everolimus compared with ful-
vestrant alone (HR, 0.63 [95% CI, 0.42-0.92]; log-rank
P = .01) (Figure 2).
In patients with measurable disease, objective response
rate on thebasis of local assessment for patients receiving ful-
vestrant alonewas 25.0%; for those receiving fulvestrant plus
daily vistusertib, 30.4%; for those receiving fulvestrant plus
intermittent vistusertib, 28.6%; and for those receiving ful-
vestrant plus everolimus, 41.2% (Table). Central assessment
showedconsistent results.Mediandurationof response inpa-
tients assigned to fulvestrant alonewas 16.7months (95%CI,
10.8-19.3 months); fulvestrant plus daily vistusertib, 11.8
months (95% CI, 8.4-13.7 months); fulvestrant plus intermit-
tentvistusertib,9.4months (95%CI, 5.9-14.5months); and ful-
vestrant plus everolimus, 17.6 months (95% CI, 9.1-19.1
months).
Overall survival results were relatively immature at the
time of the analysis, with a total of 96 deaths: 36 of 101 pa-
tients (35.6%) in the daily vistusertib group, 26 of 95 patients
(27.4%) in the intermittent vistusertib group, 21 of 66 pa-
tients (31.8%) in the fulvestrant alone group, and 13 of 64 pa-
tients (20.3%) in the fulvestrant plus everolimus group. Sur-
vival was longer in patients assigned to fulvestrant plus
everolimus compared with fulvestrant plus daily vistusertib
(HR,0.49[95%CI,0.28-0.86]; log-rankP = .02).Therewasalso
a trend toward improved OS in patients assigned to fulves-
trant plus everolimus compared with fulvestrant alone (HR,
0.56 [95% CI, 0.28-1.09]; log-rank P = .09).
Discussion
TheMANTA trial is the first trial to our knowledge to compare
a dual mTOR inhibitor with a rapamycin analogue in post-
menopausal women with ER-positive advanced or meta-
staticbreast cancer.The trialdidnotmeet itsprimaryendpoint
and failed to demonstrate a benefit of vistusertib plus fulves-
trant comparedwith fulvestrant alone.Furthermore, bothvis-
tusertibgroupswere inferior to treatmentwith fulvestrantplus
everolimus. As these clinical results are in contrast with the
evidence from in vitro and in vivo preclinical models, show-
ingsubstantial synergistic activitybetweenfulvestrantandvis-
tusertibandalso superior activityofvistusertib comparedwith
everolimus in endocrine-sensitive and -resistant breast can-
cermodels,18 it is important to assesswhat factorsmight have
contributed to the failure of vistusertib in this trial.
All 4 patient groups were well balanced in terms of base-
line patient and disease characteristics (eTable 1 in Supple-
ment 2) and the results of the fulvestrant alone group and the
fulvestrant plus everolimus group are consistent with results
from other clinical trials, making it unlikely that patient se-
lection or possible imbalances are the key driver for the ob-
served results.
Table. Primary and Key Secondary Efficacy End Points
End Point
Fulvestrant Plus Daily
Vistusertib (n = 101)
Fulvestrant Plus Intermittent
Vistusertib (n = 95) Fulvestrant (n = 66)
Fulvestrant Plus
Everolimus (n = 64)
PFS, median
(95% CI), mo
7.6 (5.9-9.4) 8.0 (5.6-9.9) 5.4 (3.5-9.2) 12.3 (7.7-15.7)
HR vs fulvestrant
(95% CI)
0.88 (0.63-1.24) 0.79 (0.55-1.12) NA NA
P value .46 .16 NA NA
HR vs fulvestrant
plus everolimus
(95% CI)
0.63 (0.45-0.90) 0.71 (0.49-1.01) 0.63 (0.42-0.92) NA
P value .01 .06 .01 NA
Objective response
rate, % (95% CI)
30.4 (20.5-41.8) 28.6 (18.8-40.0) 25.0 (14.0-38.9) 41.2 (27.6-55.8)
Clinical benefit
rate, % (95% CI)
43.0 (31.9-54.7) 39.0 (28.0-50.8) 38.5 (25.3-53.0) 56.9 (42.2-70.7)
Duration of
response median
(95% CI), mo
11.8 (8.4-13.7) 9.4 (5.9-14.5) 16.7 (10.8-19.3) 17.6 (9.1-19.1)
Duration of clinical
benefit median
(95% CI), mo
12.0 (11.8-16.6) 13.4 (11.2-18.9) 16.7 (12.8-20.2) 14.3 (12.2-18.6)
Overall survival
median
(95% CI), mo
27.1 (20.0-NR) 24.2 (20.6-NR) 24.4 (17.3-NR) NR
Abbreviations: HR, hazard ratio; NA, not applicable; NR, not reached; PFS, progression-free survival.
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Another question iswhether a comparable dose intensity
was maintained across the different treatment groups. How-
ever, given that there was no difference in the median num-
ber and percentage of missed treatment days of vistusertib
or everolimus, as well as in the percentage of patients
requiring at least 1 dose reduction of everolimus or vistu-
sertib, or in the percentage of patients discontinuing treat-
ment for reasons other than disease progression or death, it
seems unlikely that the lack of observed activity of vistu-
sertib can be attributed to differences in treatment adher-
ence and dose intensity.
Instead, the results raise the question whether the se-
lected doses of vistusertib might not have been adequate to
fully exert its established preclinical activity. The doses and
schedules within the MANTA trial were based on the maxi-
mum tolerated doses established in a phase 1 trial of vistu-
sertib and fulvestrant.16 This study used similar criteria for
dose-limiting toxic effects as the dose-finding trials for
everolimus.24-26Consequently, AE profileswere largely com-
parable between the daily vistusertib group and the everoli-
mus group.
However, given that vistusertib inhibits both mTORC1
and mTORC2 complexes, a possible explanation could be
that the toxic effect–mandated doses of vistusertib achieved
only suboptimal inhibition of the mTORC1 complex and that
the residual activity of 4E-BP1 is sufficient to negate a sub-
stantial treatment effect.14 Similar observations have been
made with pan-PI3K inhibitors and have ultimately resulted
in the development of α-specific, β-sparing PI3K inhibitors
that are currently in phase 3 trials in a similar indication.
Alternative explanations for the observed results could be
that inhibition of the mTORC2 complex has limited clinical
relevance in breast cancer and/or that everolimus might
have additional effects independent of mTORC1 inhibition.
Figure 2. Kaplan-Meier Plot of Progression-Free Survival (PFS)
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As these questions are critical for the future development of
agents of the same class, efforts should be made to further
evaluate the hypothesis. One way of testing this would be to
compare direct target inhibition and downstream effects in
tumor samples, but tissue samples while patients were
undergoing treatment were not available from the MANTA
trial.
As a positive result, the MANTA trial demonstrated that
the combination of fulvestrant plus everolimus significantly
increases PFS compared with fulvestrant alone, providing
further evidence of the benefits of everolimus for the treat-
ment of postmenopausal women with ER-positive breast
cancer after loss of response to AIs. The observed benefits in
PFS are remarkably similar to the results of the PrE0102 ran-
domized phase 2 trial, which reported that addition of
everolimus to fulvestrant improved median PFS from 5.1 to
10.3 months (HR, 0.61; P = .02).27 A similar benefit was also
observed for the combination of everolimus and exemes-
tane in the BOLERO-2 (Breast Cancer Trials of Oral Everoli-
mus–2) phase 3 trial.10 The preliminary OS data suggest a
trend toward improved OS, but results must be interpreted
with caution as, at the time of this analysis, only 30% of the
overall OS events had occurred.
To our knowledge, the MANTA trial is also the first trial
to directly compare a continuous daily treatment schedule
with a high-dose pulsatile schedule. Preclinical studies have
suggested that intermittent, high-dose treatment might be a
means to achieve more complete suppression of mTOR sig-
naling and could lead to an increase in apoptosis but might
also improve the therapeutic index. Although we did not
observe relevant differences in any of the efficacy end
points (including response rates) between the 2 schedules
selected for this trial, intermittent dosing was associated
with a lower rate of rash or stomatitis (albeit at the cost of
higher rates of short-term nausea and vomiting), suggesting
that it might be of interest to further evaluate this hypoth-
esis in future trials. As the same caveat regarding the effec-
tive vistusertib dose and the degree of mTORC1 inhibition
applies, this trial was ultimately unable to definitively
answer the hypotheses around administration of high-dose
pulsatile treatment.
Limitations
This trial has some limitations. The main limitations are the
small sample size and the open-label design.
Conclusions
Overall, the MANTA trial provides important evidence that
dual mTOR inhibition is inferior to mTORC1 inhibition with
the rapamycin analogue everolimus, possibly as a result of a
toxic effects–mandated compromise in the degree of
mTORC1 inhibition owing to the simultaneous inhibition of
mTORC2. High-dose intermittent pathway inhibition could
not improve the antitumor activity in this randomized trial
but was associated with an improved safety profile and
might be further evaluated in the future with other agents.
The results presented here do not support further evalua-
tion of vistusertib in ER-positive metastatic breast cancer,
but also raise important questions around the future of this
class of drugs.
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